| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Dec―15 |
Current advances in recombinant porcine reproductive and respiratory syndrome virus vaccines in plants |
Marco Costantini, Marcello Donini |
| 2 |
[GO] |
2025―Mar―12 |
Derivatives of MOPS: promising scaffolds for SARS coronaviruses Macro domain-targeted inhibition |
Oney Ortega Granda, Karine Alvarez, Benjamin Morin, Bruno Canard, François Ferron, Nadia Rabah |
| 3 |
[GO] |
2023―Oct―16 |
Differential specificity of SARS-CoV-2 main protease variants on peptide versus protein-based substrates |
Fernanda R. Rocho, Scott J. Snipas, Anwar Shamim, Wioletta Rut, Marcin Drag, Carlos A. Montanari, Guy S. Salvesen |
| 4 |
[GO] |
2023―Sep―02 |
Identification of a novel inhibitor of SARS-CoV-2 main protease: an in silico, biochemical, and cell-based approach |
Aditya Trivedi, Vandana Kardam, Krishna Kishore Inampudi, Sudhanshu Vrati, Dharmender Gupta, Aekagra Singh, Sarala Rani Kayampeta, Mohan Babu Appaiahgari, Deepak Sehgal |
| 5 |
[GO] |
2023―Apr―26 |
Gene silencing of endothelial von Willebrand factor reduces the susceptibility of human endothelial cells to
SARS-CoV
-2 infection |
Giulia Furini, Alessandro De Carli, Rossella Fonnesu, Pietro Giorgio Spezia, Francesca Scebba, Mauro Pistello, Michele Lai, Vincenzo Lionetti |
| 6 |
[GO] |
2023―Apr―04 |
Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses |
Ashlesha Deshpande, Nobert Schormann, Mike S. Piepenbrink, Luis Martinez Sobrido, James J. Kobie, Mark R. Walter |
| 7 |
[GO] |
2022―Oct―21 |
A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection |
Drugan K. Brady, Aashi R. Gurijala, Liyu Huang, Ali A. Hussain, Audrey L. Lingan, Olivia G. Pembridge, Brina A. Ratangee, Tristan T. Sealy, Kyle T. Vallone, Thomas P. Clements |
| 8 |
[GO] |
2022―Aug―26 |
Core fucose-specific
Pholiota squarrosa
lectin (
PhoSL
) as a potent broad-spectrum inhibitor of
SARS-CoV
-2 infection |
Kazuhiko Yamasaki, Naruhiko Adachi, Mya Myat Ngwe Tun, Akihito Ikeda, Toshio Moriya, Masato Kawasaki, Tomoko Yamasaki, Tomomi Kubota, Izuru Nagashima, Hiroki Shimizu, Hiroaki Tateno, Kouichi Morita |
| 9 |
[GO] |
2022―Aug―02 |
Effects of natural
RNA
modifications on the activity of
SARS-CoV
-2
RNA
-dependent
RNA
polymerase |
Ivan Petushkov, Daria Esyunina, Andrey Kulbachinskiy |
| 10 |
[GO] |
2022―May―01 |
Emerging clinically tested detection methods for COVID-19 |
Milagros Castellanos, Álvaro Somoza |
| 11 |
[GO] |
2022―Feb―02 |
SARS-CoV-2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion |
Federica Quaglia, Edoardo Salladini, Marco Carraro, Giovanni Minervini, Silvio C.E. Tosatto, Philippe Le Mercier |
| 12 |
[GO] |
2021―Oct―20 |
Crystal structures of the SARS-CoV-2 nucleocapsid protein C-terminal domain and development of nucleocapsid-targeting nanobodies |
Zhenghu Jia, Chen Liu, Yuewen Chen, Heng Jiang, Zijing Wang, Jialu Yao, Jie Yang, Jiaxing Zhu, Boqing Zhang, Zhiguang Yuchi |
| 13 |
[GO] |
2021―Oct―15 |
Cellular senescence as a source of SARS-CoV-2 quasispecies |
Ioannis Karakasiliotis, Nefeli Lagopati, Konstantinos Evangelou, Vassilis G. Gorgoulis |
| 14 |
[GO] |
2021―Sep―07 |
Protons to Patients: targeting endosomal Na
+
/H
+
exchangers against COVID-19 and other viral diseases |
Hari Prasad |
| 15 |
[GO] |
2021―Sep―07 |
Spotlight on COVID-19: eighteen months on |
Serena Zacchigna, Alessandro Marcello, Lawrence Banks |
| 16 |
[GO] |
2021―Jul―19 |
COVID-19 vaccines: what do we know so far? |
Paraminder Dhillon, Daniel Altmann, Victoria Male |
| 17 |
[GO] |
2021―Jul―06 |
Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2 |
Hongchun Lin, Xinxin Ma, Fang Xiao, Hua Su, Yaling Shi, Yuntao Liu, Lan Song, Zhongde Zhang, Chun Zhang, Hui Peng |
| 18 |
[GO] |
2021―Jul―03 |
The role of T cell immunity in COVID-19 severity amongst people living with type II diabetes |
ZhenWei Marcus Tong, Emma Grant, Stephanie Gras, Melanie Wu, Corey Smith, Helen L. Barrett, Linda A. Gallo, Kirsty R. Short |
| 19 |
[GO] |
2021―Jun―29 |
Targeting Neuropilins as a viable SARS-CoV-2 treatment |
Sarvenaz Sarabipour, Feilim Mac Gabhann |
| 20 |
[GO] |
2021―May―17 |
Neurological consequences of neurovascular unit and brain vasculature damages: potential risks for pregnancy infections and COVID-19-babies |
Marco Rasile, Eliana Lauranzano, Filippo Mirabella, Michela Matteoli |
| 21 |
[GO] |
2021―May―10 |
Infection-induced inflammation from specific inborn errors of immunity to COVID-19 |
Cheng-Lung Ku, I-Ting Chen, Ming-Zong Lai |
| 22 |
[GO] |
2021―Apr―17 |
Host PDZ-containing proteins targeted by SARS-Cov-2 |
Célia Caillet-Saguy, Fabien Durbesson, Veronica V. Rezelj, Gergö Gogl, Quang Dinh Tran, Jean-Claude Twizere, Marco Vignuzzi, Renaud Vincentelli, Nicolas Wolff |
| 23 |
[GO] |
2021―Mar―23 |
Non-optimal codon usage preferences of coronaviruses determine their promiscuity for infecting multiple hosts |
Gon Carmi, Alessandro Gorohovski, Sumit Mukherjee, Milana Frenkel-Morgenstern |
| 24 |
[GO] |
2021―Mar―12 |
New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3’-5’ exoribonucleolytic activity on SARS-CoV-2 |
Margarida Saramago, Cátia Bárria, Vanessa G. Costa, Caio S. Souza, Sandra C. Viegas, Susana Domingues, Diana Lousa, Cláudio M Soares, Cecília M Arraiano, Rute G. Matos |
| 25 |
[GO] |
2021―Feb―23 |
The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection |
Eugene Merzon, Ilan Green, Shlomo Vinker, Avivit Golan-Cohen, Alessandro Gorohovski, Eva Avramovich, Milana Frenkel-Morgenstern, Eli Magen |
| 26 |
[GO] |
2020―Dec―02 |
The Structural Basis of Accelerated Host Cell Entry by SARS-CoV-2
† |
Murat Seyran, Kazuo Takayama, Vladimir N. Uversky, Kenneth Lundstrom, Giorgio Palé, Samendra P. Sherchan, Diksha Attrish, Nima Rezaei, Alaa A.A. Aljabali, Shinjini Ghosh, Damiano Pizzol, Gaurav Chauhan, Parise Adadi, Tarek Mohamed Abd El-Aziz, Antonio G Soares, Ramesh Kandimalla, Murtaza Tambuwala, Sk. Sarif Hassan, Gajendra Kumar Azad, Pabitra Pal Choudhury, Wagner Baetas-da-Cruz, Ángel Serrano-Aroca, Adam M. Brufsky, Bruce D. Uhal |
| 27 |
[GO] |
2020―Oct―30 |
The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection |
Darren Z.L. Mok, Candice Yuen Yue Chan, Eng Eong Ooi, Chan Kuan Rong |
| 28 |
[GO] |
2020―Oct―24 |
Proteomic characteristics of bronchoalveolar lavage fluid in critical COVID-19 patients |
Hao-Long Zeng, Chen Di, Jingjun Yan, Qing Yang, Qiang-Qiang Han, Shu-Sheng Li, Liming Cheng |
| 29 |
[GO] |
2020―Sep―27 |
Announcing the winners of our COVID-19 Creative Communication Competition |
Paraminder Dhillon |
| 30 |
[GO] |
2020―Sep―27 |
Spotlight on COVID-19: from biology to therapy and prevention |
Serena Zacchigna, Alessandro Marcello, Lawrence Banks |
| 31 |
[GO] |
2020―Sep―27 |
Vitamin D to prevent COVID-19: recommendations for the design of clinical trials |
Carlos A. Camargo, Adrian R. Martineau |
| 32 |
[GO] |
2020―Aug―13 |
Nicotine and the nicotinic cholinergic system in COVID-19 |
Yousef Tizabi, Bruk Getachew, Robert L. Copeland, Michael Aschner |
| 33 |
[GO] |
2020―Aug―01 |
Tumor markers as an entry for SARS-CoV-2 infection? |
Pu Xia, Anna Dubrovska |
| 34 |
[GO] |
2020―Jul―23 |
Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study |
Eugene Merzon, Dmitry Tworowski, Alessandro Gorohovski, Shlomo Vinker, Avivit Golan Cohen, Ilan Green, Milana Frenkel Morgenstern |
| 35 |
[GO] |
2020―Jul―21 |
COVID-19, Cilia, and Smell |
Wei Li, Ming Li, Guangshuo Ou |
| 36 |
[GO] |
2020―Jul―12 |
Sympathetic activation: a potential link between comorbidities and COVID-19 |
Andrea Porzionato, Aron Emmi, Silvia Barbon, Rafael Boscolo-Berto, Carla Stecco, Elena Stocco, Veronica Macchi, Raffaele De Caro |
| 37 |
[GO] |
2020―Jun―05 |
COVID-19 breakthroughs: separating fact from fiction |
Paraminder. Dhillon, Manuel. Breuer, Natasha. Hirst |
| 38 |
[GO] |
2020―May―23 |
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2 |
Cassandra L. Atzrodt, Insha Maknojia, Robert D.P. McCarthy, Tiara M. Oldfield, Jonathan Po, Kenny T.L. Ta, Hannah E. Stepp, Thomas P. Clements |
| 39 |
[GO] |
2020―May―19 |
Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing |
Oleg O. Glebov |
| 40 |
[GO] |
2020―May―17 |
Ligand-centered assessment of SARS-CoV-2 drug target models in the Protein Data Bank |
Alexander Wlodawer, Zbigniew Dauter, Ivan Shabalin, Miroslaw Gilski, Dariusz Brzezinski, Marcin Kowiel, Wladek Minor, Bernhard Rupp, Mariusz Jaskolski |
| 41 |
[GO] |
2020―Mar―19 |
Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population? |
J.L. Olds, N. Kabbani |
